Notice NOT-NR-24-005 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-103 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center clinical trials involving more than one clinical center. Proposed trials should be hypothesis-driven, have the potential to change clinical practice and/or public health, and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-24-102 from the NIH Guide for Grants and Contracts. This FOA invites applications for investigator-initiated, high-risk multi-center observational studies involving more than one clinical center. Proposed studies should be hypothesis-driven and focus on a disease relevant to the mission of NIDDK. Planning activities must be completed prior to submission and are not permitted under this FOA. Applicants who require a planning phase may first apply for an implementation planning cooperative agreement (U34; see TEMP9971).Consultation with NIDDK Scientific/Research staff is strongly encouraged prior to the submission of either a U34 or U01 application.

Funding Opportunity PAR-24-094 from the NIH Guide for Grants and Contracts. NIDDK supports investigator-initiated, high-risk multi-center (more than one center) clinical studies through a two-part process that may include an implementation planning cooperative agreement (U34). The U34 is designed to: 1) Permit early peer review of the rationale for the proposed clinical study; 2) Permit assessment of the design and protocol of the proposed study; 3) Provide support for the development of documents needed for the conduct of the study, including a manual of operations; and 4) Support the development of other essential elements required for the conduct of the clinical study. The proposed clinical study should be hypothesis-driven and focus on a disease in the mission of NIDDK. Consultation with NIDDK scientific staff is strongly encouraged prior to the submission of the U34 application.

Notice NOT-MH-24-145 from the NIH Guide for Grants and Contracts

Notice NOT-DC-24-013 from the NIH Guide for Grants and Contracts

Notice NOT-MD-24-004 from the NIH Guide for Grants and Contracts

Notice NOT-DC-24-015 from the NIH Guide for Grants and Contracts

Notice NOT-DE-24-010 from the NIH Guide for Grants and Contracts

Notice NOT-DE-24-009 from the NIH Guide for Grants and Contracts

Notice NOT-AG-23-078 from the NIH Guide for Grants and Contracts

Notice NOT-MD-24-002 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-089 from the NIH Guide for Grants and Contracts. This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs that propose to support intensive supervised research training and career development experiences for clinician scientists (Scholars) leading to research independence in the area of substance use and substance use disorder research.

Notice NOT-CA-24-024 from the NIH Guide for Grants and Contracts

Funding Opportunity PAR-24-105 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) invites applications for the continued support and advancement of the Mutant Mouse Resource and Research Centers (MMRRC). The MMRRC consortium is expected to facilitate research by identifying, acquiring, evaluating, characterizing, cryopreserving, and distributing mutant mouse strains to qualified biomedical investigators. A regional network of four MMRRCs and an Informatics, Coordination and Service Center (ICSC) collectively serve the needs of the biomedical research community for transgenic, knockout and other genetically-engineered mutant mice and related biomaterials. MMRRC strains are held to the highest standards to optimize reproducibility of studies and assure scientific rigor and transparency; all submitted strains are thoroughly reviewed and documented and include additional quality control measures. The Program Director/Principal Investigator (PD/PI) of each MMRRC in addition to the major resource activities is required to develop a small high risk, high return, research pilot project that complements the goals and needs of the MMRRC consortium.

Notice NOT-OD-24-052 from the NIH Guide for Grants and Contracts

Funding Opportunity RFA-HG-24-006 from the NIH Guide for Grants and Contracts. This Notice of Funding Opportunity (NOFO) encourages applications for renewal of the NHGRI Technology Development Coordinating Center (TDCC). The TDCC will continue to provide an infrastructure for enhancing and advancing efforts supported by NHGRIs Genome Technology Program. The Centers activities will include facilitating opportunities for new research collaborations to advance technology development and dissemination. The TDCC will also develop outreach strategies and resources to engage the broader biomedical research community and provide an Opportunity Funds Program to support innovative small-scale work.

Notice NOT-OD-24-031 from the NIH Guide for Grants and Contracts

Notice NOT-MH-24-105 from the NIH Guide for Grants and Contracts

Notice NOT-MH-24-100 from the NIH Guide for Grants and Contracts